<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463707</url>
  </required_header>
  <id_info>
    <org_study_id>BP101-SD02-RUS</org_study_id>
    <nct_id>NCT03463707</nct_id>
  </id_info>
  <brief_title>BP101 for Adults With Female Sexual Dysfunction</brief_title>
  <official_title>Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Confirmatory Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivix LLX</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ivix LLX</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to confirm efficacy and safety of study drug BP101 in female patients with with
      decrease or loss of sexual desire, which is equal to acquired generalized hypoactive sexual
      desire disorder (HSDD). Patients will be randomized in 1:1 ratio to either BP101 or placebo
      arms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Satisfying sexual events</measure>
    <time_frame>Baseline and 4 weeks of treatment</time_frame>
    <description>Change in the number of satisfying sexual events (SSEs), standardized to the 28-day period, after 4 weeks of treatment, compared with the baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfying sexual events</measure>
    <time_frame>Baseline and 4 and 8 weeks of follow-up</time_frame>
    <description>Change in the number of satisfying sexual events (SSEs), standardized to the 28-day period, after 4 and 8 weeks of follow-up, compared with the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orgasms</measure>
    <time_frame>Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up</time_frame>
    <description>Change in the number of orgasms, standardized to the 28-day period, after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index total score</measure>
    <time_frame>Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up</time_frame>
    <description>Change in the Female Sexual Function Index (FSFI) total score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.
FSFI total score ranges from 2.0 to 36.0, where higher score represents better sexual function. FSFI total score is a sum of FSFI individual domains scores (individual domains are: Desire, Arousal, Lubrication, Orgasm, Satisfaction, and Pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index Desire domain score</measure>
    <time_frame>Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up</time_frame>
    <description>Change in the Female Sexual Function Index (FSFI) Desire domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.
FSFI Desire domain score ranges from 1.2 to 6.0, where higher score represents better sexual desire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index Arousal domain score</measure>
    <time_frame>Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up</time_frame>
    <description>Change in the Female Sexual Function Index (FSFI) Arousal domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.
FSFI Arousal domain score ranges from 0 to 6.0, where higher score represents better sexual arousal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index Lubrication domain score</measure>
    <time_frame>Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up</time_frame>
    <description>Change in the Female Sexual Function Index (FSFI) Lubrication domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.
FSFI Lubrication domain score ranges from 0 to 6.0, where higher score represents better vaginal lubrication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index Orgasm domain score</measure>
    <time_frame>Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up</time_frame>
    <description>Change in the Female Sexual Function Index (FSFI) Orgasm domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.
FSFI Orgasm domain score ranges from 0 to 6.0, where higher score represents better orgasm sensation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index Satisfaction domain score</measure>
    <time_frame>Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up</time_frame>
    <description>Change in the Female Sexual Function Index (FSFI) Satisfaction domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.
FSFI Satisfaction domain score ranges from 0.8 to 6.0, where higher score represents better sexual satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index Pain domain score</measure>
    <time_frame>Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up</time_frame>
    <description>Change in the Female Sexual Function Index (FSFI) Pain domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.
FSFI Pain domain score ranges from 0 to 6.0, where higher score represents lower pain sensation during sexual intercourse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Distress Scale-Revised Total score</measure>
    <time_frame>Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up</time_frame>
    <description>Change in the Female Sexual Distress Scale-Revised (FSDS-R) total score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.
FSDS-R total score ranges from 0 to 52, where higher score represents higher level of distress related to sexual activities. A score of ≥11 discriminates between women with female sexual disfunction (score of ≥11) and no female sexual disfunction (score of &lt;11).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Distress Scale-Revised Item 13 score</measure>
    <time_frame>Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up</time_frame>
    <description>Change in the Female Sexual Distress Scale-Revised (FSDS-R) Item 13 score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.
FSDS-R Item 13 score ranges from 0 to 4, where higher score represents higher level of bother by low sexual desire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function according to the Female Sexual Function questionnaire</measure>
    <time_frame>Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up</time_frame>
    <description>Change in the Female Sexual Function questionnaire (FSF) score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.
FSF score ranges from 0 to 36, where higher score represents better sexual function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's assessment of efficacy of the therapy according to the Patient Global Impression of Improvement</measure>
    <time_frame>Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up</time_frame>
    <description>The patient's assessment of efficacy of the therapy according to the Patient Global Impression of Improvement (PGI-I) after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>During 12 weeks after start of treatment (4 weeks of treatment and 8 weeks of follow-up)</time_frame>
    <description>Frequency of adverse events reporting, including serious adverse events, in treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Hypoactive Sexual Desire Disorder</condition>
  <condition>Female Sexual Dysfunction</condition>
  <condition>Sexual Desire Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment with BP101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BP101</intervention_name>
    <description>Investigational product BP101, nasal spray</description>
    <arm_group_label>Treatment with BP101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to Investigational product BP101, nasal spray</description>
    <arm_group_label>Treatment with placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged from 21 to 50 years old, who have signed informed concent, with a regular
             menstrual cycle (STRAW stages -5 to -3).

          -  Decrease or loss of sexual desire (ICD-10 code: F-52.0) corresponding to the diagnosis
             of acquired generalized hypoactive sexual desire disorder (HSDD) according to
             Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM4), criteria.

          -  Current HSDD episode lasting not less than 24 weeks.

          -  Not less than 15 scores according to the FSDS-R (Distress) Total Score.

          -  Stable monogamous relationship with one sexually active male sexual partner lasting at
             least a year. The partner is physically available not less than 50% of time during a
             month.

          -  Consent to attempt to have a sexual intercourse at least twice a month, if she has a
             desire.

          -  Consent to complete a diary every day during the screening period and assessment of
             the baseline state (in this period diary records must cover ≥80% days), during the
             therapy and subsequent follow-up.

          -  Consent to use adequate methods of contraception throughout the study.

        Exclusion Criteria:

          -  Any prohibited treatments.

          -  Other mental disorders or psychiatric diseases.

          -  Diagnosed Decrease or loss of sexual desire (HSDD) is situational (reactive) or
             lifelong.

          -  Score ≥ 20 according to the Beck Depression Inventory during the screening. Patients
             with 16 to 19 scores according to Beck's inventory may be included in the study
             unless, in the investigator's opinion, an actual depressive disorder is observed in
             the patient.

          -  Inflammatory diseases of pelvic organs, infections of the genitourinary system,
             cervicitis, interstitial cystitis, vulvodynia or severe atrophy of the vaginal
             epithelium, precluding normal sexual activity.

          -  Surgical interventions (other than cosmetic surgeries) on reproductive organs in past
             medical history (ovariectomy, hysterectomy, obvious scars from childbirth-related
             perineal stitches, etc), resulting in pain/dyspareunia, and/or precluding sexual
             contacts, and/or requires hormonal replacement treatment, and/or lead to the loss of
             sensibility while sexual contact.

          -  Pregnant and nursing women or non-lactating women during the first 12 months after
             childbirth.

          -  Consumption of more than 5 portions of alcoholic drinks per week or alcohol addiction,
             drug addiction or drug abuse in the past. One portion of an alcoholic drink means 360
             ml of beer, 120 ml of wine or 30 ml of a strong alcoholic drink.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women aged from 21 to 50 years old</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniil G. Nemenov, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ivix LLX</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniil G. Nemenov, MD</last_name>
    <phone>4959747401</phone>
    <phone_ext>159</phone_ext>
    <email>daniil.nemenov@bioprocess.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Алтайский государственный медицинский университет</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kuban State Medical University</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the Russian Academy of Sciences</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>N.A. Alexeev Moscow Psychiatric Clinical Hospital #1</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Obstetrics, Gynecology and Perinatology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Medical Research Center of Psychiatry and Addiction named after V.P. Serbsky</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Psychiatry Hospital №1</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orenburg Regional Clinical Psychiatric Hospital No. 2</name>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City psychiatric hospital №7 named after academician I.P. Pavlov</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Doctor SAN Ltd.</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Narcological Dispensary</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>OrKli Hospital LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research center Eco-Safety LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantin Zakharov, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samara Psychiatric Hospital</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Engels Psycyatric hospital</name>
      <address>
        <city>Saratovskaya</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Psychiatric Hospital of St. Sofia</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinic &quot;Hundred Years&quot;</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bashkir State Medical University</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Clinical Psychiatric Hospital</name>
      <address>
        <city>Yaroslavl'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

